The Long Run with Luke Timmerman

Timmerman Report
undefined
Apr 12, 2023 • 1h 11min

Ep133: Catherine Stehman-Breen on Epigenetic Editing Therapies

Catherine Stehman-Breen, CEO of Boston-based Chroma Medicine, on developing epigenetic editing therapies.
undefined
Mar 28, 2023 • 1h 6min

Ep132: Eric Dobmeier on Treating Kidney Disease

Eric Dobmeier, CEO of Seattle-based Chinook Therapeutics, on new strategies for treating kidney diseases.
undefined
Mar 14, 2023 • 1h 6min

Ep131: Ryan Watts on Neuroscience Drug R&D

Ryan Watts, CEO of South San Francisco-based Denali Therapeutics, on neuroscience drug discovery and development.
undefined
Feb 28, 2023 • 1h 9min

Ep130: David Hallal on a Life in Biotech & the Cell Therapy Wave

David Hallal, CEO of ElevateBio, on a long career in biotech and the coming 50-year opportunity in cell therapy and gene therapy.
undefined
4 snips
Feb 14, 2023 • 1h 12min

Ep129: Joanne Smith-Farrell on Engineered B-Cell Therapies

Joanne Smith-Farrell, CEO of Cambridge, Mass.-based Be Biopharma, on Engineered B-Cell Therapies for Cancer & Rare Diseases.
undefined
Feb 1, 2023 • 1h 1min

Ep128: Rick Berke on Building a Biotech Journalism Outlet to Last

Rick Berke, co-founder and executive editor of STAT, on building a biotech journalism outlet to last.
undefined
Jan 20, 2023 • 1h 10min

Ep127: Jeb Keiper on Computational Drug Discovery

Jeb Keiper, CEO of Nimbus Therapeutics, on computational drug discovery, an unusual business model, and an important new Tyk2 inhibitor for psoriasis and other forms of autoimmunity.
undefined
Jan 3, 2023 • 1h 12min

Ep126: DA Wallach on Becoming a Biotech VC

DA Wallach, founder and general partner of TIME Bioventures, on becoming a biotech venture investor.
undefined
Dec 19, 2022 • 1h 5min

Ep125: Barry Greene on a New Drug for Depression

Barry Greene, CEO of Cambridge, Mass.-based Sage Therapeutics, on plans to introduce a new type of treatment for depression and postpartum depression.
undefined
Nov 8, 2022 • 1h 10min

Ep124: Shehnaaz Suliman on Delivery of Genetic Medicines

Shehnaaz Suliman, CEO of ReCode Therapeutics, on lipid nanoparticle delivery of genetic medicines.

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app